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The renal PT*IIPTHrP receptor is down-regulated in rats with chronic
renal failure. Hypocalcemia, hyperphosphatemia, and resistance to the
action of PTH are well characterized features in the setting of advanced
chronic renal failure (CRF). Although the underlying mechanisms are
ill-understood, clinical and experimental evidence points to both PTH
receptor down-regulation and post-receptor abnormalities in their
pathogenesis. In the present study we have examined the effect of
advanced CRF in rats on the renal expression of PTH/PTHrP receptor
(PTH-R). CRF was created by a standard two-step operation (5/6
nephrectomy). Four weeks thereafter, 19 uremic rats were compared
with 23 sham-operated rats. Uremic rats had higher mean (± SD) plasma
creatinine levels than control rats, 164 107 LM versus 43 5 LM,
respectively. They also had higher plasma phosphorus and iPTH levels,
4.70 1.71 m versus 2.59 0.37 m and 561 336 versus 27 18
pg/mi, respectively. Mean plasma total calcium and blood ionized
calcium were significantly lower in uremic than in control rats, 2.13
0.06 m versus 2.61 0.10 m and 1.07 0.11 versus 1.31 0.06 mM,
respectively. Mean plasma calcitriol concentration was also signifi-
cantly lower in uremic than in control rats, 39.8 14.6 and 80.4 15.2
pg/ml, respectively. Nine out of the 19 rats were examined for renal
PTH-R gene expression. We show for the first time that the level of
PTH-R mRNA in the kidney of uremic rats was markedly decreased
compared with that of normal rats, the ratio PTH-R mRNA//3-actin
mRNA being 0.47 0.12 versus 0.99 0.23, respectively, and the ratio
PTH-R mRNA/28S being 8.9 4.7 versus 19.6 11.1, respectively.
This decrease was associated with a marked reduction in PTH-sensitive
adenylyl cyclase activity in crude renal membranes from uremic rats.
The values of basal adenylyl cyclase activity and subsequently after
stimulation by forskolin and NaF were also significantly reduced in
comparison to that of normal rats. These data indicate that rats with
severe CRF have reduced renal PTH-R expression, associated with
diminished basal and PTH-sensitive adenylyl cyclase activity. These
abnormalities could be important in the pathogenesis of the secondary
hyperparathyroidism of CRF.
Parathyroid hormone (PTH) tightly regulates plasma calcium
and phosphate concentrations by modulating the activity of
specific cells in bone and kidney [1]. In kidney, PTH is known
to increase calcium reabsorption and to stimulate phosphate
excretion. PTH also activates the renal synthesis of active
vitamin D metabolites which, in turn, are able to stimulate
intestinal absorption of calcium and phosphate. In bone, PTH
stimulates the release of calcium and phosphate by increasing
osteoclast-mediated bone resorption [1].
PTH performs these actions through binding to specific
high-affinity receptors located on osteoblastic and renal cells [1,
21. The binding of PTH to its receptor leads to the production of
several second messengers, including cAMP [3, 4], calcium [5,
61, and inositol trisphosphates [4—7]. It is known that the
number of PTH receptors (PTH-R) in these target organs is not
static and can be regulated by many factors such as the serum
PTH concentration [8—10]. Cultured renal cells as well as bone
cells become refractory in their PTH binding and PTH-stimu-
lated cAMP production after prolonged exposure to PTH [11—
14] suggesting a homologous down-regulation of the PTH-R
[11—13].
It is known that hypocalcemia plays an important role in the
pathogenesis of secondary hyperparathyroidism in chronic re-
nal failure [15, 16]. Several factors have been identified as the
cause of hypocalcemia in uremia including decreased intestinal
calcium absorption caused by an altered vitamin D metabolism
[17], hyperphosphatemia [18], and an impaired calcemic re-
sponse to PTH [19—21]. It has been thought that the lower
calcemic response to PTH in CRF is caused by PTH-R down-
regulation in PTH target organs [19—241.
To analyze whether the renal PTH-R could be involved in the
mechanisms of hypocalcemia in chronic renal failure we have
examined its expression in the kidney. The recent cloning of
PTH-R eDNA from a rat osteosarcoma cell line (ROS 17/2.8)
[25] has permitted us to measure the level of renal PTH-R
mRNA. In addition, we have assessed its functional status by
the determination of the PTH-stimulated cAMP production in
crude renal membrane preparation. The results show that
hypocalcemic rats with chronic renal failure have reduced renal
PTH-R mRNA expression and reduced basal and PTH-sensi-
tive adenylyl cyclase activity.
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Animals
Male 12- to 14-week-old Wistar AF rats (IFFA CREDO,
Lyon, France) weighing 250 to 300 g were fed ad libitum with a
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phosphate-rich diet containing 1.2% P, 0.6% Ca, 16% casein,
and 2,000 lU/kg vitamin D3 in order to obtain severe secondary
hyperparathyroidism. Animals were allowed to free access to
food and deionized water.
Creation of chronic renal failure
Chronic renal failure was created by a standard two-step
operation [26]. Rats were anesthetized by pentobarbital given
i.p. During the first surgery, 2/3 of the left kidney were removed
by cutting off both poles after decapsulation, and complete
hemostasis was obtained by electrocoagulation. Seven days
later, total right nephrectomy was performed. Twenty-three
rats of the same sex, age and weight, fed with normal diet,
underwent sham operation and were regarded as the control
group.
Blood biochemistry
Four weeks after surgery, animals were anesthetized by
injection of pentobarbital i.p. before sacrifice and a blood
sample was obtained by aortic puncture. An aliquot of hepa-
rinized blood was used for ionized Ca determination (ICA1
Ionized Calcium Analyzer, Radiometer, Copenhagen, Den-
mark). The remaining blood was centrifuged at 3,000 g for 20
minutes. Plasma was stored at —50°C until assays were per-
formed. Plasma total calcium, phosphorus, total protein con-
centration, urea and creatinine were determined by standard
laboratory methods performed on multiparametric analyzer
(Hitachi 717 analyzer, Boehringer Mannheim, Germany).
Plasma immunoreactive parathyroid hormone (iPTH) was mea-
sured with a rat PTH (IRMA) kit (Immutopics, Inc., California,
USA) [27] recognizing the N-terminal portion of the hormone.
Mean plasma iPTH (± SEM) measured in 12 normal rats was
43.8 21.6 pg/ml, the lowest and the highest values were 15 and
88 pg/nil, respectively. Plasma calcitriol was measured by
radioreceptor assay (Nichols Institute, San Juan Capistrano,
California, USA) using calf thymus receptor according to the
method of Hollis [28].
Preparation of crude renal membranes
The cortex of kidneys from control and uremic rats was
dissected and crude renal membranes were prepared by a
modification of the procedure described by Marx, Fedak and
Aurbach [291. After homogenization in a 30% (vollvol) buffer
solution containing 0.25 M sucrose, 10 mM Tris and 1 mM
Na2EDTA, pH 7.5, the homogenized tissue was diluted 1:1 with
buffer solution and centrifuged at 4°C in a Sorvall ultracentri-
fuge. When the rotor speed reached 4,500 rpm, centrifugation
was stopped and the supernatant was collected. After the
second identical centrifugation the supernatant was centrifuged
at 4,500 rpm for 15 minutes. The supernatant was discarded and
the upper portion of the resulting "double-layered" pellet was
resuspended in 3 volumes of a buffer solution containing 10 msr
Tris, 1 m Na2EDTA, pH 7.5 and stored at —80°C until used
for the determination of protein concentration and adenylyl
cyclase activity. Protein content was measured using the bicin-
choninic acid (BCA) protein assay (Pierce, Rockford, Illinois,
USA), a modification of the original Lowry method [30].
Adenylyl cyclase assay and cAMP measurement
The adenylyl cyclase assay was a modification of the proce-
dure described by Carnes, Anast and Forte [31]. The reaction
mixture contained a renal membrane preparation of 75 g of
protein, 0.1% bovine serum albumin, 50 mM Tris-HC1 (pH 7.5),
1.7 mM MgCI2, 1.2 ifiM ATP, 7 m phosphocreatine, 1 mM
3-isobutyl-1-methylxanthine (IBMX), and 1.08 units/tube of
creatine kinase, This preparation was incubated for 30 minutes
at 37°C with vehicle (acetic acid 10 mM), 10 m NaF, 1 mM
forskolin, or I LM (1-34) bovine PTH. All samples were
acetylated, and the amount of cAMP generated was measured
using a RIA kit (Cyclic AMP RIA Pasteur kit, ERIA Diagnos-
tics Pasteur, France).
RNA preparation and Northern blot hybridization
Total RNA from homogenized renal tissues was prepared
using the acid-guanidinium-isothiocyanate-phenol-chloroform
extraction method [32], RNA preparations were denatured and
separated by electrophoresis (1% agarose/2.2 M formaldehyde
gel), transferred to a nitrocellulose membrane (Schleicher &
Schuell, Keene, New Hampshire, USA), and baked (2 hr,
80°C). The filters were hybridized with a cDNA probe which
was a 1.8 kb, Barn HI-Not I fragment corresponding to most of
the rat PTH/PTHrP receptor cDNA' s coding region [25]. It was
32P-labeled using the random-priming method to a specific
activity of 1 x i09 cpm/g. All filters were prehybridized for
three to four hours at 42°C with a solution containing 50% of
formamide, 6.6x standard saline citrate (SSC), 0.1% SDS, S x
Denhardt's solution, 200 p.g/ml of salmon sperm DNA and 0.01
M EDTA. The labeled probe was then added to the prehybrid-
ization solution (1 x 106 cpm/ml) and the filters were incubated
overnight (16 to 18 hours) at 42°C. They were then washed
twice, 30 minutes at 42°C with 300 ml of lx SSC plus 0.1%
SDS, and 30 minutes at 65°C with the same solution. The filters
were exposed to an autoradiographic film with an intensifying
screen for 4 to 15 days at —80°C. After hybridization with the
PTH/PTHrP receptor probe and exposure, the filters were
washed for 30 minutes at 95°C in 0.01% SDS, and rehybridized
with either a 450 bp-Hinf I fragment of a human beta-actin
eDNA [33], which was also 32P-labeled by random-priming or a
30 base pairs oligomer (5' GGG TGG AGG CCG CCG CGA
GTG CAG ATC TTG 3') complementary to the 28S ribosomal
RNA which was 2P-end-labeled using the bacteriophage poly-
nucleotide kinase [34]. The abundance of PTH-R and fl-actin
and 28S RNAs was quantified by densitometric analysis (Scan
Analysis, Biosoft, UK). The PTH-R mRNA expression was
normalized to the densitometric values obtained for the f3-actin
probe and for the 28S nbosomal RNA either after ethidium
bromide (EB) staining or after hybridization. Results are ex-
pressed as the ratio PTH-R/J3-actin mRNA, PTH-R/28S (EB),
and PTH-R128S ribosomal RNA.
Statistical analysis
Results have been expressed as means SD and statistical
significance determined by the unpaired Student's t-test or
ANOVA test, as appropriate. P values less than 0.05 were
considered significant.
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Results
Plasma biochemistry
Table 1 shows the selected biochemical parameters obtained
at the moment of sacrifice. As expected, uremic rats had higher
plasma creatinine levels than control rats, 164 107 LM versus
43 5 xM, respectively. They also had higher plasma phos-
phorus and iPTH levels, 4.70 1.71 m versus 2.59 0.37 mM
and 561 336 versus 27 18 pg/mI, respectively. Mean total
plasma calcium and blood ionized calcium were significantly
lower in uremic than in control rats, 2.13 0.26 m versus 2.61
0.10 m and 1.07 0.11 m versus 1.31 0.06 mM,
respectively. Mean plasma calcitriol concentration was also
significantly lower in uremic than in control rats, 39.8 14.6
and 80.4 15.2 pg/mi, respectively. A positive correlation was
found between plasma creatinine levels and iPTH (r = 0.36, N
= 35, P < 0.03). Blood ionized calcium correlated inversely
with plasma creatinine and iPTH levels (r —0.56, N = 13, P
<0.03, and r =
—0.81, N = 26, P < 0.001, respectively). Mean
total plasma protein concentration was significantly lower in
rats with chronic renal failure than in normal rats, 52.1 5.3
g/liter versus 55.0 2.2 g/liter.
Adenylyl cyclase activity
Basal adenylyl cyclase activity in crude renal membranes of
uremic rats was significantly lower than that of normal animals
(Fig. 1), the total amount of cAMP produced was 15.1 8.2
pmol cAMP/p.g of protein at 37°C for 30 mm in normal rats and
8.8 1.2 pmol cAMP/pg of protein at 37°C for 30 minutes in
rats with CRF. Adenylyl cyclase activity after stimulation by 1
LM of bPTH (1-34) was markedly reduced in rats with CRF as
compared with normal rats, total cAMP produced was 20.0
12.3 versus 67.2 4.8 pmol cAMP/pg of protein at 37°C for 30
minutes, respectively. NaF- and forskoiin-stimulated adenylyl
cyclase activities were similarly decreased in crude renal mem-
branes of uremic rats (Fig. 1). Table 2 shows the results
expressed relative to basal adenylyl cyclase activity. After this
correction, only the PTH-stimulated adenylyl cyclase activity
was significantly reduced in renal membranes from uremic rats
(Table 2). In contrast, neither NaF- nor forskoiin-stimulated
cyclase activity showed any difference when expressed as
relative values.
Fig. 1. Effect of NaF, forskolin, and PTH on renal adenylyl cyclase
activity expressed as pmol of cAMP produced/30 mm at 37°C/g of
protein. Seventy-five g of protein from the renal cortex membrane
preparation were incubated for 30 mm at 37°C with vehicle (acetic acid
10 mM), 10 msi NaF, 1 m forskolin, or I /LM (1-34) bovine PTH, in
presence of 1 mri IBMX. Symbols are: (•) normal rats; (D) uremic
rats. Results are means 5D of duplicate determinations from 6
experiments. * P < 0.01, ** P < 0.001.
Table 2. Adenylyl cyclase activity expressed as absolute values and
values relative to the basal activity
Absolute values Relative values
Control CRF Control CRF
Basal 15.1 8.2 8.8 1.2 1 1
NaF 76.6 10.0 52.5 8.2 5.1 0.6 5.9 0.9
Forskolin 76.5 11.8 49.0 24.6 5.1 0.8 5.6 2.8
PTH 67.2 4.0 20.2 12.0 4.4 0.3 2.3 l.4a
Seventy-five micrograms of protein from the renal cortex membrane
preparation were incubated for 30 mm at 37°C with either vehicle (acetic
acid 10 mM), 10 mr'x NaF, 1 m forskolin, or 1 LM (1-34) bovine PTH,
in presence of 1 ms IBMX. Abbreviations are: CRF, chronic renal
failure; NaF, sodium fluoride. Values are means SD of duplicate
determinations from 6 experiments.
a p < 0.001
PTH-R mRNA
The steady-state levels of the PTH-R mRNA were dramati-
cally decreased in rats with CRF as compared to control
animals. Figure 2 shows the PTH-R expression in two repre-
sentative pairs of 11 control and 11 CRF animals. The two
uremic rats had a severe CRF with plasma creatinine levels
higher than 300 /LM. Figure 3 shows the results of PTH-R gene
expression in five rats with different degrees of CRF. The level
of PTH-R mRNA expression tended to correlate inversely with
plasma creatinine concentration, but not with that of plasma
iPTH. However, the small number of animals did not permit
establishment of the degree of significance of the relation with
plasma creatinine levels. There was no significant difference in
the renal J3-actin gene expression between control and CRF
animals; the ratio ,!3-actin/28S (EB) was 20.8 1 and 16.8 6 in
control and CRF rats, respectively (Table 3). This excludes the
possibility that the observed difference in the renal PTH-R gene
expression between control and CRF rats was caused by a
Table 1. Biochemical parameters obtained at the moment of sacrifice 100
Control
(N=23)
Chronic renal
failure
(N= 19)
Plasma creatinine LM 43.4 5 164.0 1o7
Plasma urea mst 6.0 1.41 22.7 20.9a
Plasma total protein glliter 55.0 2.2 52.1 53b
Blood ionized calcium m 1.31 0.06 1.07 0.11°
Plasma total calcium mw 2.61 0.10 2.13 0.26°
Plasma phosphorus mw 2.59 0.37 4.70 l.71a
Plasma iPTH pg/mi 27 18 561 336°
Plasma calcitriol pg/mi 80.4 15.2 39.8 14.6°
Abbreviation is iPTH, rat immunoreactive parathyroid hormone.
Results are expressed as mean SD.
° P < 0.001; b p < 0.05
80
60
40
20
0
II III I 11111 I
•1
r.
608 Urena Ct a!: PTH receptor down-regulation
28 S
18 S
Control CRF Control CRF
PTH/PTHrP
receptor mRNA
Fig. 2. The upper pane! shows Northern blot
analysis of kidney tissue from two
representative pairs of ii control and ii
uremic (CRF) rats. Twenty tg of total RNA
were loaded in each lane, transferred to a
nitrocellulose membrane and hybridized with
the rat PTHIPTHrP receptor probe. The
autoradiograph was developed after a three
day exposure with an intensifying screen at
—80°C. The lower panel shows the
corresponding photograph of the 28S and 18S
nbosomal RNA stained by ethidium bromide.
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FIg. 3. The upper panel shows Northern blot analysis of kidney tissue from 5 pairs of control and uremic animals (CRF). Twenty of total RNA
were loaded in each lane, transferred to a nitrocellulose membrane and hybridized with the rat PTHIP'FHrP receptor probe. The autoradiograph
was developed after a three day exposure with an intensifying screen at —80°C. The number indicated above each pair of CRF rats represents the
corresponding plasma creatinine level in sM. The lower panel shows the results of the hybridization of the same filter with the i-actin probe after
a two day exposure.
Table 3. Densitometric data from Northern blot analysis of kidney tissue (shown in Fig. 3) from 5 pairs of control and uremic animals
Densitometry Ratio
PTH-RJ PTH-RJ p-actin/
PTH-R j3-actin 28S (EB) $-actin 28S (EB) 28S (EB)
Control 18.6 2.9 19.2 3.4 1.2 0.6 0.99 0.2 19.6 11.1 20.8 1
CRF 10.5 3.9 21,6 3.9 1.3 0.2 0.47 0.1 8.9 4.7 16.8 6
Results are expressed as arbitrary units for the densitometric values and as the ratio VfH-RJ-actin, PTH-R128S (EB), and 13-actin/28S (EB).
Abbreviations are: PTH-R, parathyroid hormone receptor; 28S (EB), densitometric values obtained from the ethidium bromide staining of the 28S
ribosomal RNA; CRF, chronic renal failure.
different RNA loading or an artifact in the RNA preparation. To
further verify this we have looked at the renal expression of the
28S ribosomal RNA as another housekeeping gene (Fig. 4).
There was no difference in the 28S ribosomal RNA expression
between control and CRF animals. The ratios corresponding to
Figure 4 were PTH-RI/3-actin 1.15 0.02 versus 0.64 0.02,
PTH-RJ2SS ribosomal RNA 0.78 0.01 versus 0.46 0.05, and
f3-actinl28S ribosomal RNA 0.67 0.01 versus 0.71 0.07, in
control and CRF rats, respectively (Fig. 4). Only the ratios
PTH-R13-actin and PTH-R128S ribosomal RNA were statisti-
cally different (P < 0.01).
Discussion
Prolonged exposure of cells, tissues or organs to a hormone
can lead to a subsequent impaired response to that hormone.
This phenomenon, known as desensitization, has been shown
to exist for PTH in many experimental models, including
cultured renal cells [12], bone tumor cells [11, 13, 14], vitamin
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28S ribosomal28S RNA
Fig. 4. Northern blot analysis of kidney tissue from one pair of control
and two pairs of uremic rats. Twenty g of total RNA were loaded in
each lane, transferred to a nitrocellulose membrane and hybridized with
the rat PTH/PTHrP receptor probe. The autoradiograph was developed
after a three day exposure with an intensifying screen at —80°C. The
same ifiter was hybridized with the f3-actin probe and with a 30 base
pairs oligomer complementary to the 28S ribosomal RNA sequence.
D-deficient humans and animals [22, 24, 34], aged animals [9,
10], chronic renal failure [19—24], and dietary-induced hyper-
parathyroidism [35]. Such studies have led to the conclusion
that most of the desensitization to PTH is due to the loss of
PTH-R sites on the target cells. The present study demonstrates
for the first time that the PTH-R mRNA is down-regulated in
the kidney of uremic rats. The down-regulation was associated
with reduced PTH-sensitive adenylyl cyclase activity both in
absolute and relative terms. This suggests that the decrease of
PTH-R mRNA was at least in part responsible for the observed
renal receptor desensitization to PTH in uremia.
Several mechanisms could theoretically account for the de-
creased expression of the renal PTH-R gene including elevated
circulating PTH levels, low plasma calcitriol levels, hyperphos-
phatemia, hypocalcemia, and/or other factors that are abnormal
in the uremic state. Among these factors, to date only PTH has
been demonstrated to affect the PTH-R mRNA expression.
Prolonged treatment of cultured osteoblast-like cells (ROS
17/2.8) with PTH has recently been shown to lead to a moderate
reduction of PTH-R mRNA [14]. In keeping with this observa-
tion, in the present in vivo study chronically elevated circulating
PTH levels were probably necessary, but not sufficient, to
account entirely for the reduced renal PTH-R transcript in rats
with CRF. We found that renal PTH-R mRNA expression
tended to correlate inversely with plasma creatinine but not
with plasma iPTH. Likewise, Bover et al found that a reduction
of PTH levels to the normal range did not correct the down-
regulation of the PTH-R in azotemic rats [37]. These observa-
tions favor the view that renal PTH-R mRNA down-regulation
in vivo may require factors other than increased plasma PTH
levels.
The difference found in the basal adenylyl cyclase activity
between normal and uremic renal membranes in the present
study suggests the possibility that the activity of the enzyme is
decreased or the function is altered in uremia. These two
hypotheses are, however, unlikely since the fivefold increase in
adenylyl cyclase activity after stimulation with forskolin, which
is believed to act primarily on the catalytic unit of the enzyme,
and the comparable increase after NaF, which activates
directly, were similar in both groups, in contrast to the effect of
PTH which was significantly less marked in uremic rats, even
when expressed as percent of stimulation over basal activity.
We do not know whether the decrease in the basal enzyme
activity in uremic animals was due to a diminished stimulatory
or an increased inhibitory tone exerted on the catalytic unit of
the adenylyl cyclase. A similar difference has recently been
reported between spontaneously hypertensive rats (SHR) and
their normotensive controls (WKY) [38]. Altogether, these
findings suggest that other factors which are abnormal in the
uremic state may account for the differences observed in basal
enzyme activity.
Theoretically, the down-regulation of the renal PTH-R could
contribute to the development of the hyperphosphatemia and
hypocalcemia observed in CRF by at least two mechanisms.
First, this down-regulation could directly decrease the phospha-
tune effect of PTH resulting in phosphate retention and indi-
rectly in hypocalcemia [22]. Patel and Hsu have shown that the
decrease in urinary phosphate excretion observed in nonfasted
hyperphosphatemic rats with CRF could be overcome by the
infusion of supraphysiological doses of PTH [39]. Second, the
renal PTH-R down-regulation, in addition to the effect of
hyperphosphatemia, could lead to a depression of the PTH-
stimulated synthesis of 1,25 (OH)2D3 by the kidney with a
subsequent decrease in intestinal calcium absorption leading to
hypocalcemia. Thus, PTH-R down-regulation in the kidney
could play an important role in the development of secondary
hyperparathyroidism in the early and the advanced stages of
CRF.
It is widely believed that the main mechanism of hypocalce-
mia in CRF is the blunted skeletal response to PTH, probably
due to PTH-R down-regulation in bone [19—24]. However, the
calcemic response to PTH involves not only skeletal mobiliza-
tion of calcium, but also renal and intestinal calcium transports.
It has recently been shown that a decrease in intestinal calcium
absorption, rather than skeletal resistance, is the principal
mechanism of the impaired calcemic response to PTH in rats
with CRF [39]. A direct effect of PTH on the intestine, which
has been previously proposed by Rasmussen [40], and by our
group [41, 42], cannot be completely ruled out even though it
remains highly controversial. In keeping with such a possibility,
we have recently demonstrated the presence of PTH-R mRNA
in the intestinal tract of the rat [43].
In conclusion, our data indicate that rats with advanced
chronic renal failure have reduced PTH-R mRNA expression
and diminished basal as well as PTH-sensitive adenylyl cyclase
activity in the kidney. Whether a decrease in PTH-R expression
also exists in other PTH target tissues such as bone, remains to
be investigated. The relevance of such abnormalities for the
pathogenesis of the secondary hyperparathyroidism in CRF is
probable but their precise place has still to be defined.
Control CRF CRF
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PTH/PTHrP
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18S mRNA
-actin
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